Oncology Central

Maintenance therapy for multiple myeloma after an autologous transplant: what have we learned?

0

Current treatment for newly diagnosed multiple myeloma (MM) can be divided into different phases: induction, high-dose chemotherapy and autologous hematopoietic stem cell transplantation (auto-HSCT), consolidation and maintenance. The use of auto-HSCT, immunomodulatory agents (IMiDs) and proteasome inhibitors (PIs) in the treatment of MM have greatly improved the progression-free survival (PFS) and overall survival (OS) of these patients in the last 10–15 years [1]. Even with recent progress in therapy, almost all MM patients eventually relapse. To overcome this problem, approaches such as post-auto-HSCT consolidation and maintenance are being explored to prolong the duration of remission and delay disease progression [2–4].

Restricted Content / Members Only

You cannot view this content because It is available to members only. Please or Register to view this area.

Share:

Insights

Videos

News Headlines

Leave A Comment

Please wait...

Would you like access to more immuno-oncology content?

Register with Oncology Central to find out the latest news, opinions and journal articles published in the oncology field by leading experts.